Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "-29 5"

Looking for quality documents?
store icon
Biotech CE Dialysis Tubing – Repligen
Economy packaging provides a 10-meter supply of a particular CE tubing MWCO & flatwidth to meet the demands of ongoing & frequent dialysis applications. Product Specifications: Properties: Hydrophilic, symmetric porosity 9 MWCOs: 100-500 D, 500-1000 D, 3.5-5 kD, 8-10 kD, 20 kD, 50 kD, 100 kD, 300 kD & 1000 kD 4 Flat Widths: 10 mm, 16 mm, 24 mm & 31 mm Qty & Pkg: 10 meter/roll, wet in 0.05% sodium azide
store icon
Biotech CE Dialysis Tubing – Repligen
Economy packaging provides a 10-meter supply of a particular CE tubing MWCO & flatwidth to meet the demands of ongoing & frequent dialysis applications. Product Specifications: Properties: Hydrophilic, symmetric porosity 9 MWCOs: 100-500 D, 500-1000 D, 3.5-5 kD, 8-10 kD, 20 kD, 50 kD, 100 kD, 300 kD & 1000 kD 4 Flat Widths: 10 mm, 16 mm, 24 mm & 31 mm Qty & Pkg: 10 meter/roll, wet in 0.05% sodium azide
external link icon
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises Orders increased sequentially and greater than 20% year-over-year Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth

WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today’s webcast and conference call. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had another outstanding quarter in Q3 with 18% organic growth. We are thrilled with the momentum we
external link icon
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growth Orders grew sequentially and greater than 20% year-over-year Increasing revenue guidance to range of $715 to $735 million, which represents 12.5% -15.5% year-over-year non-COVID organic growth
WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today’s webcast and conference call. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had another outstanding quarter in Q2 with 17% organic non-COVID growth. We are very pleased with the momentum we see across the portfolio. This included
store icon
KROSFLO 20CM 10K MPES 1MM 3TC X 1.5TC STERILE – Repligen
KROSFLO 20CM 10K MPES 1MM 3TC X 1.5TC STERILE
store icon
KROSFLO 20CM 30K MPES 1MM 3TC X 1.5TC STERILE – Repligen
KROSFLO 20CM 30K MPES 1MM 3TC X 1.5TC STERILE
store icon
KROSFLO 20CM 100K MPES 1MM 3TC X 1.5TC STERILE – Repligen
KROSFLO 20CM 100K MPES 1MM 3TC X 1.5TC STERILE
store icon
KROSFLO 20CM 300K MPES 1MM 3TC X 1.5TC STERILE – Repligen
KROSFLO 20CM 300K MPES 1MM 3TC X 1.5TC STERILE
store icon
MICROKROS 20CM 1K MPES .5MM MLLXFLL 1/PK – Repligen
MICROKROS 20CM 1K MPES .5MM MLLXFLL 1/PK
store icon
MIDIKROS 20CM 5K MPES 1MM TC X FLL 1/PK STERILE – Repligen
MIDIKROS 20CM 5K MPES 1MM TC X FLL 1/PK STERILE